BTK inhibitor JNJ-64264681

{
  "id": "MLC-T-ONC-012151",
  "term": "BTK inhibitor JNJ-64264681",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, BTK inhibitor JNJ-64264681 targets, binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/btk-inhibitor-jnj-64264681/"
}